Caicun Zhou

16PUBLICATIONS
74CO-AUTHORS
Predictive and prognostic markersMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer diagnosisCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Sep 07, 2026
Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer.

|Aug 12, 2026
Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.

|Dec 01, 2025
Phase 1b Multicenter Study of SG001, a Humanized Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors.

Jian Fang, Ou Jiang, Wei Li

|Nov 14, 2025
Cost-effectiveness of PD-L1 testing to guide immunotherapy for patients with advanced non-small-cell lung cancer in China.

Fei Zhou, Yuan Li, Jian Ming

|Jun 27, 2025
Long-term safety analysis of pooled data for tislelizumab as monotherapy or in combination with chemotherapy in patients with advanced cancers.

Caicun Zhou, Rose Huang, Yuan Yuan

|May 16, 2025
Atezolizumab plus bevacizumab and chemotherapy in metastatic nonsquamous NSCLC: the randomized double-blind phase 3 IMpower151 trial.

Caicun Zhou, Xiaorong Dong, Gongyan Chen

Pageof 3

Frequent Collaborators

4 joint publications

Fei Zhou

2 joint publications

Ying Cheng

2 joint publications

Yongqian Shu

2 joint publications

Fengying Wu